Landscape Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Landscape Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-18,054	Closed	-$8.18M	–	977
2025 Q4	$8.18M	Buy	18,054 +7,570	+72%	+$3.26M	0.55%	30
2025 Q3	$4.11M	Buy	10,484 +7,405	+241%	+$3.09M	0.26%	111
2025 Q2	$1.37M	Sell	3,079 -398	-11%	-$183K	0.11%	269
2025 Q1	$1.69M	Buy	3,477 +2,194	+171%	+$1.02M	0.15%	209
2024 Q4	$517K	Buy	+1,283	New	+$595K	0.05%	407
2018 Q4	–	Sell	-1,122	Closed	-$216K	–	985
2018 Q3	$216K	Sell	1,122 -1,249	-53%	-$222K	0.02%	630
2018 Q2	$403K	Buy	+2,371	New	+$368K	0.03%	333

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Landscape Capital Management's VRTX Position: Q1 2026 in Review

Landscape Capital Management sold out of Vertex Pharmaceuticals (VRTX) in Q1 2026, closing a stake of 18,054 shares — an estimated $8.18M sold.

Landscape Capital Management first reported a position in VRTX in Q2 2018 and held it in 7 quarters. The position peaked at $8.18M in Q4 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Landscape Capital Management reported no remaining Vertex Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Landscape Capital Management sold 18,054 Vertex Pharmaceuticals shares in Q1 2026, an estimated $8.18M.
Landscape Capital Management first reported a position in Vertex Pharmaceuticals in Q2 2018 and held it in 7 quarters.
Landscape Capital Management's Vertex Pharmaceuticals position peaked at $8.18M in Q4 2025.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Landscape Capital Management's 13F filing for Q1 2026, filed 12 May 2026.